spacer
home > ebr > winter 2018 > under lock and key
PUBLICATIONS
European Biopharmaceutical Review

Under Lock and Key

A new approach to early-stage drug development is being pioneered in Cambridge with the establishment of the Milner Therapeutics Institute (1). This collaboration between pharmaceutical companies and a number of academic institutions aims to create an ecosystem for pre-competitive drug discovery by sharing data and other resources. This initiative illustrates how the increasing volume and complexity of biodata is creating the need for new data management models to ensure that researchers can access the information they need, wherever it is stored, within a secure environment.

The Milner Institute has evolved from the research agreement signed in June 2015 between the University of Cambridge, the Wellcome Trust Sanger Institute and the Babraham Institute with the pharma companies AstraZeneca, Astex and GSK. The number of affiliates has since increased to 66 (2).

Having an agreement in place has lowered the barriers of engagement. Where previously the exchange of potential drug molecules between pharma and researchers could take a year, it now takes two to three weeks.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Misha Kapushesky is founder and Chief Executive Officer of biodata management company Genestack. Prior to Genestack, he was Team Leader in Functional Genomics at the European Bioinformatics Institute (EBI), where he led a team developing pioneering bioinformatics data systems to manage and query the data EBI was archiving. The high level of industry interest made Misha realise these tools addressed a significant pain-point. Genestack has since worked closely with leading industry partners to build a bioinformatics infrastructure that makes it easy to find, combine, analyse and visualise data. Misha has participated in and led international consortia applying bioinformatics to medical research.

spacer
Dr Misha Kapushesky
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.
More info >>

White Papers

ConsulTech GmbH

ConsulTech GmbH

ConsulTech is a consulting company founded in 1992. Since then, we have been supporting biotech-nology, pharmaceutical and medical technology companies as well as research institutions with the entire process of setting-up and executing proposals for R&D projects. In projects funded by the European Commission, ConsulTech supports the coordinator by resuming administrative tasks allow-ing coordinators and partners to fully concentrate on the scientific and technical success of the pro-ject. We solve financial and administrative issues, organise meetings, take care of the timely delivery of milestones and reports and much more.
More info >>

 
Industry Events

6th Annual Single Cell Analysis Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 6th Annual Single Cell Analysis Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement